

## LICENSE AGREEMENT

### LICENSE DETAILS

**Quote ID:** Q-100706

**Customer:** AIFA - Agenzia Italiana del Farmaco (Adis Insight)

**Primary Address:** Via del Tritone 181, 187, ROMA, Rome, Italy

This License Agreement between Springer Nature Customer Service Center GmbH, Tiergartenstrasse 15-17, 69121 Heidelberg, Germany ("Licensor") and Customer incorporates the following documents:

- This License Details page including Attachment 1: Customer and Licensee Information;
- The Product Terms;
- The General Terms and Conditions incorporated herein by reference and located at [www.springernature.com/legal/ROW\\_Corporate\\_Terms\\_and\\_Conditions\\_7.0\\_sni](http://www.springernature.com/legal/ROW_Corporate_Terms_and_Conditions_7.0_sni).

When executed by both parties, this License Agreement shall be deemed effective on the earlier of (i) the earliest Commencement Date for any Product licensed hereunder, or (ii) the last date of signature by Licensor or Customer.

Offer valid until: June 27, 2024

### Quote Table (Q-100706)

Start Date: June 01, 2024 End Date: May 31, 2025

Product Family	Product Terms <sup>1</sup>	Access Type <sup>2</sup>	Customer Price <sup>3</sup> (License Fee)
AdisInsight	O	AO	€5,811.00
<b>Total</b>			<b>€5,811.00</b>

1. Label of the applicable Product Terms.

2. Indication for access type: CA = Continuing Access, AO = Access Only. However, the specific access rights are detailed in, and governed by the Product Terms relevant for the Product Family.


3. Prices do not include VAT or other applicable taxes which shall be payable in addition.

CERTAIN CONTENT MADE AVAILABLE TO LICENSEE MAY BE SUBJECT TO AND LICENSED UNDER OPEN ACCESS LICENSE TERMS ("OPEN ACCESS CONTENT"). OPEN ACCESS CONTENT IS SOLELY SUBJECT TO THE APPLICABLE OPEN ACCESS LICENSE TERMS, SPECIFIED WITHIN THE CONTENT. FOR THE AVOIDANCE OF DOUBT, PAYMENT OF LICENSE FEES IS NOT RELATED TO THE ACCESS OR USE RIGHTS WITH RESPECT TO OPEN ACCESS CONTENT.

### 1. Payment Terms

1.1 The License Fee(s) is/are due within 60 days from the date of invoice.

**IN WITNESS WHEREOF**, the parties have signed this License Agreement by their respective, duly authorized representatives on the date set forth below.

<b>CUSTOMER</b>	<b>LICENSOR</b>
Signature: _____	Signature: 
Name: _____	Name: <u>Peter Kaul</u>
Title: _____	Title: <u>General Manager</u>
Date: _____	Date: <u>March 29, 2024</u>

## **Attachment 1**

### **Customer and Licensee Information**

#### **Customer Information:**

- Legal Entity Name: AIFA - Agenzia Italiana del Farmaco (Adis Insight)
- Address: Via del Tritone 181, 187, ROMA, Rome, Italy
- Contact Individual: Jelena Ivanovich , j.ivanovic@aifa.gov.it
- Business Partner ID: 3003808089

Customer is Licensee for all purposes under the License Agreement.

Customer will supply Licensor with an initial list of its IP addresses used for the access to the Content (if not already supplied to Licensor), prior to the Commencement Date and shall notify Licensor of any IP address changes. Licensor reserves the right to confirm accuracy of the IP address(es) supplied before grant of access. Notwithstanding anything to the contrary in this License Agreement, notifications of IP address changes may be made in electronic format. Licensor's obligation to timely provide access to the Content under this License Agreement is conditioned on Licensee's provision of its IP addresses.

**Product Terms (O)**  
**AdisInsight**

**1. Term**

The Term shall begin on June 01, 2024 (the “Commencement Date”) and shall end on May 31, 2025.

**2. Reports**

Standard rights: In addition to the rights granted to Licensee in the General Terms and Conditions, Licensor hereby grants Licensee the non-exclusive, non-sublicensable and non-transferable right to create reports which may include individual items from the selected Modules solely for Licensee’s own internal purpose in connection with its own business, and not in connection with providing such reports or any data or service to any third party. Such reports may be in print or electronic format.

**3. Content**

**3.1 AdisInsight Platform Access**

Notwithstanding anything to the contrary in the General Terms and Conditions, Authorized Users are limited to the number of Authorized Users of Licensee indicated below.

Database	Module(s)	Number of Authorized Users
AdisInsight	Drugs & Deals <input type="checkbox"/>	5
AdisInsight	Trials <input type="checkbox"/>	5